Skip to main content
AmigoFish

Ep. 388 - Biotech IPOs, CAR T safety & pharma tariffs

From BioCentury This Week · · 32 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

The first biotech IPO (https://www.biocentury.com/article/660853) in a month, Electra's upsized $350 million offering, fell in its trading debut, testing investor appetite while a wave of reverse mergers showcases an alternate route to NASDAQ. On the latest BioCentury This Week podcast, BioCentury's analysts examine momentum in the biotech IPO market. The team also unpacks fatal toxicities in Novartis' autoimmune CAR-T trials (https://www.biocentury.com/article/660804) and what they reveal about manufacturing, dosing and immune biology risks across the modality. In Washington, Steve Usdin previews Heidi Overton's FDA Commissioner confirmation hearing and reports on the persistent uncertainty around pharma tariffs (https://www.biocentury.com/article/660836) ahead of the Sept. 29 deadline.

View full story: https://www.biocentury.com/article/660870

#BiotechIPO #CARTCell #FDA #PharmaTariffs #DrugDevelopment

0:00 Introduction 02:15 Biotech IPO Market 10:38 Autoimmune CAR-T Safety 21:56 FDA Commissioner Hearing 26:47 Pharma Tariff Uncertainty

To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.

Reach us by sending a text (https://www.buzzsprout.com/1035190/fan_mail/new)

Back to BioCentury This Week · Report a problem